CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Grand Pharmaceutical's CBT-001 meets primary endpoint in Phase III pterygium trial

By Public Technologies
  • Grand Pharmaceutical reported on November 5, 2026, that CBT-001 met the primary endpoints in an international Phase III pterygium trial.
  • Both doses improved eye redness and reduced lesion length compared with vehicle treatment; additional analyses are ongoing.
  • Superficial punctate keratitis was the most common adverse event at the lower dose; most cases resolved with artificial tears.
  • Developer Cloudbreak Pharma plans to discuss the findings and potential clinical and regulatory next steps with the FDA.
  • The group holds exclusive manufacturing and commercialization rights in mainland China, Hong Kong, Macao and Taiwan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12400965), on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk